220 results on '"Boch, Tobias"'
Search Results
2. Treatment of agitation in terminally ill patients with intranasal midazolam versus subcutaneous midazolam: study protocol for a randomised controlled open-label monocentric trial (MinTU Study)
3. Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms
4. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
5. Abstract: Multistage Registration of CT and Biopsy CT Images of Lung Tumors
6. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
7. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
8. Performance of the Bronchoalveolar Lavage Fluid Aspergillus Galactomannan Lateral Flow Assay With Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: A Multicenter Cohort Study
9. Abstract: Multistage Registration of CT and Biopsy CT Images of Lung Tumors
10. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
11. Understanding iron homeostasis in MDS: the role of erythroferrone
12. 67/w mit Schmerzen in der rechten Hüfte: Vorbereitung auf die Facharztprüfung: Fall 42
13. Socio-economic burden of disease: Survivorship costs for bladder cancer
14. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
15. Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
16. Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states
17. Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis
18. ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT
19. Oncogenic RAS-Pathway Activation Drives Oncofetal Reprogramming and Creates Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia
20. Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics
21. Myelodysplastische Syndrome
22. S206: ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT
23. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS
24. Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapy
25. OC 34 - ONCO-FETAL REPROGRAMMING DRIVES HIGH-RISK JUVENILE MYELOMONOCYTIC LEUKEMIA, WHICH CAN BE TARGETED BY ANTI-CD52 TREATMENT
26. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure
27. Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives
28. Exploring Genetic and Non-Genetic Changes Driving Tumor Evolution in CK-AML at Single-Cell Resolution
29. Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models
30. Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML
31. Human haematopoietic stem cell lineage commitment is a continuous process
32. Socio-economic burden of disease: survivorship costs for soft tissue sarcoma
33. Comparison of extraction methods for intracellular metabolomics of human tissues
34. Myelodysplastische Syndrome
35. The evolving landscape of new diagnostic tests for invasive aspergillosis in hematology patients: strengths and weaknesses
36. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool
37. Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects
38. Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery
39. Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma
40. Differential Effects of Omega-3 Fatty Acids on HO-1, VCAM-1, and Cytotoxicity in Endothelial Cells
41. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
42. Medical Savings Accounts: Implications on Healthcare Expenditure, Efficiency, Equity, and Financial Protection
43. 3019 – SINGLE-CELL PROTEO-GENOMIC REFERENCE MAPS OF THE HEMATOPOIETIC SYSTEM ENABLE THE PURIFICATION AND MASSIVE PROFILING OF PRECISELY DEFINED CELL STATES
44. Comparison of extraction methods for intracellular metabolomics
45. Direct comparison of galactomannan performance in concurrent serum and bronchoalveolar lavage samples in immunocompromised patients at risk for invasive pulmonary aspergillosis
46. Biomarker-based diagnostic work-up of invasive pulmonary aspergillosis in immunocompromised paediatric patients – is Aspergillus PCR appropriate?
47. Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
48. Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states
49. Whole genome analysis of Aspergillus fumigatus isolates for identification of novel mutations in candidate genes possibly be involved in mediation of azole resistance
50. Leitlinie - ICD-10 C93.10/C93.11 : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.